All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Belantamab mafodotin for RRMM: Real-world data from the ALFA study
Bookmark this article
|
The noninterventional, retrospective ALFA study assessed the real-world safety and efficacy of belantamab mafodotin, a B-cell maturation agent (BCMA)-targeted antibody–drug conjugate, in adult patients with relapsed/refractory multiple myeloma (RRMM).1 The study included 184 patients treated with belantamab mafodotin monotherapy in 45 centers in France from April 2020 to June 2021. Results were published in the European Journal of Haematology by Roussel et al.1 |
| Key learnings: |
|
The overall response rate was 32.7%, with 20.4% and 12.3% of patients achieving at least a very good partial response (≥VGPR) and partial response, respectively, consistent with clinical trial data. Response rates were consistent across subgroups. |
|
Median progression-free survival (PFS) and overall survival (OS) were 2.4 months and 8.8 months, respectively. Notably, patients who responded to treatment had significantly improved survival outcomes, with a median PFS and OS of 20.6 months and not reached, respectively, in patients achieving ≥VGPR, underscoring the importance of response depth in patient outcomes. |
|
The safety profile highlighted that 86.4% of patients experienced adverse events (AEs), primarily ocular (56.0%), including keratopathy (41.8%), which was manageable with appropriate ophthalmological monitoring and interventions. |
|
These findings affirm that belantamab mafodotin can be effectively and safely used in routine clinical practice in a broad range of patients with RRMM, irrespective of their characteristics, though careful management of ocular AEs is necessary. |
- Roussel M, Texier N, Nael V, et al. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study. Eur J Haematol. 2024;113(3):310-320. DOI: 1111/ejh.14222
Your opinion matters
0 votes - 88 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox